image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.09
5.83 %
$ 68.1 M
Market Cap
-2.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CTSO stock under the worst case scenario is HIDDEN Compared to the current market price of 1.09 USD, Cytosorbents Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CTSO stock under the base case scenario is HIDDEN Compared to the current market price of 1.09 USD, Cytosorbents Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CTSO stock under the best case scenario is HIDDEN Compared to the current market price of 1.09 USD, Cytosorbents Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CTSO

image
$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
25.1 M REVENUE
-30.88%
-16.8 M OPERATING INCOME
46.21%
-20.7 M NET INCOME
27.32%
-14.4 M OPERATING CASH FLOW
33.37%
-669 K INVESTING CASH FLOW
28.50%
9.33 M FINANCING CASH FLOW
-35.54%
9.15 M REVENUE
6.24%
-4.05 M OPERATING INCOME
7.98%
-7.88 M NET INCOME
-237.77%
-2.34 M OPERATING CASH FLOW
4.84%
-124 K INVESTING CASH FLOW
58.37%
167 K FINANCING CASH FLOW
268.49%
Balance Sheet Cytosorbents Corporation
image
Current Assets 21.6 M
Cash & Short-Term Investments 3.28 M
Receivables 7.32 M
Other Current Assets 11 M
Non-Current Assets 25.8 M
Long-Term Investments 0
PP&E 20.5 M
Other Non-Current Assets 5.25 M
6.92 %15.45 %23.23 %43.30 %11.09 %Total Assets$47.4m
Current Liabilities 9.82 M
Accounts Payable 3.34 M
Short-Term Debt 453 K
Other Current Liabilities 6.03 M
Non-Current Liabilities 26.4 M
Long-Term Debt 12.4 M
Other Non-Current Liabilities 14 M
9.21 %16.63 %34.31 %38.60 %Total Liabilities$36.3m
EFFICIENCY
Earnings Waterfall Cytosorbents Corporation
image
Revenue 25.1 M
Cost Of Revenue 0
Gross Profit 25.1 M
Operating Expenses 41.9 M
Operating Income -16.8 M
Other Expenses 3.93 M
Net Income -20.7 M
30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)25m025m(42m)(17m)(4m)(21m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-66.81% OPERATING MARGIN
-66.81%
-82.46% NET MARGIN
-82.46%
-186.54% ROE
-186.54%
-43.74% ROA
-43.74%
-40.84% ROIC
-40.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytosorbents Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20.7 M
Depreciation & Amortization 439 K
Capital Expenditures -284 K
Stock-Based Compensation 3.76 M
Change in Working Capital 0
Others 2.09 M
Free Cash Flow -14.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytosorbents Corporation
image
CTSO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Cytosorbents Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
47.3 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA). prnewswire.com - 1 week ago
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J. , April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller. prnewswire.com - 2 weeks ago
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. prnewswire.com - 2 weeks ago
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Company's Rights Offering in January 2025. prnewswire.com - 4 weeks ago
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H. C. Wainwright Thomas Kerr - Zacks Small Cap Research Operator Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Corporation Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlight Conference Call. seekingalpha.com - 1 month ago
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights 2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of Revenue PRINCETON, N.J. prnewswire.com - 1 month ago
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release. prnewswire.com - 1 month ago
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it is postponing its previously announced earnings call scheduled for March 6, 2025 to allow more time to complete the annual financial audit following the recent passing of the Company's Vice President and Corporate Controller from natural causes. globenewswire.com - 1 month ago
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J. globenewswire.com - 3 months ago
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P. globenewswire.com - 4 months ago
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. globenewswire.com - 5 months ago
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today. seekingalpha.com - 5 months ago
8. Profile Summary

Cytosorbents Corporation CTSO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 68.1 M
Dividend Yield 0.00%
Description Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Contact 305 College Road East, Princeton, NJ, 08540 https://www.cytosorbents.com
IPO Date Aug. 8, 2006
Employees 149
Officers Mr. Peter J. Mariani CPA Chief Financial Officer Jodi Hoover Executive Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. Chief Medical Officer Dr. Robert H. Bartlett M.D. Co-Chairman of Cardiac Surgery Advisory Board & Consultant Mr. Christopher Cramer M.B.A., M.S. Senior Vice President of Business Development Ms. Kathleen P. Bloch CPA, M.B.A. Advisor Dr. Christian Steiner M.D. Executive Vice President of Sales & Marketing Mr. Vincent J. Capponi M.S. President & Chief Operating Officer Dr. Phillip P. Chan M.D., Ph.D. Chief Executive Officer & Director